Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Indiabulls Pharma...

    Indiabulls Pharma raises Rs 155 crore from Clermont Group

    Written by Ruby Khatun Khatun Published On 2017-12-09T14:53:15+05:30  |  Updated On 16 Aug 2021 4:40 PM IST

    Mumbai: Indiabulls Pharmaceuticals has raised Rs 155 crore from Singapore-based investment firm Clermont Group.


    Indiabulls Pharmaceuticals is a wholly owned company of Indiabulls group, founded in July 2016 currently having product segments of both chronic and acute therapies, and span across health, wellness and cosmeceutical categories with 300 products under its stable, some of which have been introduced in India for the first time to meet patients' needs.


    A recent report in Times of India states, Clermont Group, run by New Zealand-based billionaire investor-turned-philanthropist Richard Chandler has acquired about 9 percent stake in the company for Rs 155 crore, valuing Indiabulls Pharmaceuticals at about Rs 1,800 crore.


    Clermont Group currently has large minority stakes in Axis Bank, Indiabulls Real Estate and Ujjivan Financial Services, collectively prized at nearly Rs 4,000 crore now.


    The New Zealand-born Chandler was recently in the news for his philanthropic initiative named Co-Impact, which has Bill & Melinda Gates, Jeff Skoll (of eBay fame) and The Rockefeller Foundation as his core-partners. Infosys chairman Nandan Nilekani and his wife Rohini have also joined Chandler's initiative through EkStep Foundation, co-founded by the couple .


    The daily reports that currently, the manufacturing partners of the company have facilities with WHO/EU GMP certification and compliant with USFDA cGMP requirements.


    The company will use the investments to strengthen its healthcare products and services in India, with the intention of being amongst the top 10 players in the coming decade.


    Nikhil Chari, CEO, Indiabulls Pharmaceuticals told TOI, "This investment by Chandler would provide some growth capital to the company's ambitions of becoming a leading provider of healthcare products and services in India. The company is aiming to reshape the Indian pharmaceutical industry landscape by providing next-generation therapies to patients at affordable prices."


    The Indiabulls Group has businesses across housing finance, consumer finance, real estate and pharmaceuticals sectors.

    Axis BankClermont GroupfundFund raisefund raisingfundingGMP certificationIndiabulls GroupIndiabulls PharmaIndiabulls Real EstateIndian pharmaceutical industryInvestmentNikhil ChariRaisesRichard ChandlerUjjivan Financial ServicesUSFDAWHO
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok